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Abstract
Background: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated epithelial malignancy
that exhibits distinct geographical and ethnic prevalence. Although the contemporary therapeutic approach of
radio-/chemotherapy provides excellent results for patients with early-stage disease, it is far from satisfactory
for those with disease remission and distant metastasis. Promising therapeutic strategies for advanced and
relapsed NPC are still lacking. We recently identified and characterized a cancer stem-like cell (CSC) subpopulation in
NPC that appeared to play an important role in tumor progression. Microarray analysis revealed downregulation of
several stemness-inhibiting miRNAs in these CSC cells. Among these miRNAs, miR-96 and miR-183 showed the
highest fold change and were selected to elucidate their role in repressing NPC CSC properties.
Methods: MiR-96 and miR-183 expression in NPC CSCs was detected by qRT-PCR. Transient and stable transfection
was performed in EBV-positive NPC C666-1 cells to examine the effects of ectopic expression of miR-96 and miR-183 on
repressing cell growth and CSC properties. Anchorage-dependent (colony formation) and anchorage-independent
(tumor sphere formation) growths of these miR-96 and miR-183 expressing cells were determined. Expression of
multiple CSC markers and related molecules were accessed by flow cytometry and Western blotting. The
tumorigenicity of the stable miR-96- and miR-183-transfected NPC cells was examined in an in vivo nude mice model.
Results: Downregulation of miR-96 and miR-183 was confirmed in NPC spheroids. Using transient or stable transfection,
we showed that ectopic expression of miR-96 and miR-183 suppressed cell growth and tumor sphere formation
in NPC. Reduced NICD3 and NICD4 in miR-96- and miR-183-expressing NPC cells suggests the involvement of the
NOTCH signaling pathway in their tumor suppressive function. Finally, we showed that the tumorigenicity of cells
stably expressing miR-183 was significantly inhibited in the in vivo nude mice model.
Conclusions: miR-183 is a tumor-suppressive miRNA in EBV-associated NPC. Its abilities to suppress CSC properties in
vitro and effectively reduce tumor growth in vivo shed light on its role as a potential therapeutic target.
Keywords: Nasopharyngeal carcinoma, Epstein-Barr virus, microRNA, Cancer stem-like cells, NOTCH
* Correspondence: kwlo@cuhk.edu.hk
1Department of Anatomical and Cellular Pathology, State Key Laboratory in
Oncology in South China, Prince of Wales Hospital, The Chinese University of
Hong Kong, Shatin, N.T., Hong Kong
2Li Ka Shing Institute of Health Science, The Chinese University of Hong
Kong, Shatin, N.T., Hong Kong
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cheung et al. BMC Cancer  (2016) 16:495 
DOI 10.1186/s12885-016-2525-5
Background
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr
virus (EBV)-associated epithelial malignancy that ex-
hibits distinct geographical and ethnic prevalence [1, 2].
Although the contemporary therapeutic approach of
radio-/chemotherapy provides excellent results for pa-
tients with early-stage disease, it is far from satisfactory
for those with disease remission and distant metastasis,
which are highly fatal. [3]. Identification of promising
therapeutic targets for patients with advanced disease is
urgently needed. Despite continuous efforts in NPC re-
search, our understanding of the mechanisms that
regulate tumor progression is limited. In the past dec-
ade, the cancer stem-like cell (CSC) subpopulation was
proposed to play a critical role in local relapse and me-
tastasis in human cancers [4, 5]. These CSCs have the
ability to self-renew, differentiate, and sustain propaga-
tion and are commonly unresponsive to conventional
treatments [6]. Targeting of the CSC subpopulation and
suppression of the properties of CSCs are believed to
enhance the efficacy of radiotherapy and chemoradio-
therapy [6]. In our earlier study, we identified and char-
acterized an NPC CSC subpopulation that is suggested
to be a potential culprit for the metastasis of this EBV-
associated malignancy [7, 8]. Using microarray analysis,
we revealed a number of differentially expressed genes
in transcription regulation (e.g., FOXN4 and GLI1), im-
mune response (CCR7), and transmembrane transport
(e.g., ABCC3 and ABCC11) in the spheroids [7]. Aside
from these cellular genes, microRNA (miRNA) micro-
array analysis also identified a number of differentially
expressed miRNAs in the NPC CSCs. MiRNAs are
small (approximately 22 nucleotides) non-coding RNAs
that regulate gene expression [9]. Since the elucidation
of the roles of miRNAs in developmental processes, stud-
ies have focused on their involvement in cancer [9, 10].
Interestingly, certain miRNA clusters, such as the miR-
183-96-182 cluster, play crucial roles in regulating
stemness properties and drug resistance in cancer cells
[11]. Wellner et al. showed that overexpression of miR-
183, miR-203, and miR-200c decreases the sphere-
forming capacity of pancreatic cancer cells [12]. It has
been suggested that repression of these stemness-inhibiting
miRNAs maintains the stem cell phenotype and is im-
plicated in cancer progression [13–16]. Among the
differentially expressed miRNAs identified in NPC
spheroids, several stemness-inhibiting miRNAs in-
cluding miR-96 and miR-183 were downregulated in
the NPC CSCs. In the present study, we confirmed that
miR-96 and miR-183 have the highest fold changes. We
then performed a functional study to elucidate whether
miR-96 and miR-183 are NPC tumor suppressors that re-
press CSC properties. Our findings demonstrated that the
ectopic expression of miR-96 and miR-183 suppressed the
colony- and sphere-forming ability of NPC cells in vitro.
However, only NPC cells stably expressing miR-183 could
inhibit tumor formation in vivo in a nude mice model.
MiR-183 has a potent effect on the suppression of CSC
properties in vitro and in vivo and may play a contributory
role in NPC tumorigenesis.
Methods
Cell culture and transfections
An EBV-positive NPC cell line C666-1 was used in this
study [17]. It was cultured in RPMI-1640 (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10 % fetal bovine
serum (Invitrogen, Carlsbad, CA, USA). Tumor spheres
(anchorage-independent growth) were cultured as previ-
ously described [7]. C666-1 cells were transiently trans-
fected with miR-96, miR-183, Ambion® anti-miR™ miRNA
inhibitors, or negative controls (Ambion, Austin, TX,
USA) by Lipofectamine™ 2000 (Invitrogen) according to
the manufacturer’s instructions. C666-1 cells stably over-
expressing miRNA were generated by lentiviral transfec-
tion with a vector expressing miR-96 or miR-18 and a
miR-negative control vector according to the manufac-
turer’s protocol (Lenti-miR™ microRNA precursor clones,
SBI System Biosciences, Palo Alto, CA, USA). Successfully
transfected cells were identified and confirmed by the ex-
pression of green fluorescence protein.
Microarray analysis
Total RNA was extracted from sphere-forming and par-
ental C666-1 cells and subjected to microarray analysis
(Agilent Technologies Inc., Santa Clara, CA, USA) as
described previously [7]. Aberrantly expressed miRNAs
detected in the array were then subjected to quantita-
tive reverse transcription and polymerase chain reac-
tion (qRT-PCR) for subsequent validation.
qRT-PCR analysis
Total RNA from each treatment group was extracted
using TRIZOL® reagent (Invitrogen). qRT-PCR using
SuperScript™ III Reverse Transcriptase (Invitrogen) was
performed for the detection of 5 s for data normalization.
For detection of miRNAs, reactions were carried out with
TaqMan MicroRNA Assays (Life Technologies / Thermo
Fisher Scientific, MA, USA) according to the manufac-
turer’s instructions. The assays employed pre-designed,
target-specific stem-loop reverse transcription miRNA
primers (Thermo Fisher Scientific) for the mature miRNAs.
All qRT-PCRs were performed in triplicates on an ABI
7500 real-time PCR system (Applied Biosystems, Foster
City, CA, USA) as instructed by the manufacturer.
Western blotting
The expression of various proteins in the miRNA-
expressing and control NPC C666-1 cells was detected by
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Western blotting. The antibodies against SOX2 (Abcam,
Cambridge, MA, USA), OCT4 (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA), BMI1 (Millipore, Billerica,
MA, USA), NOTCH3/NICD3 (Orbigene, San Diego,
CA, USA), NOTCH4/NICD4 (Orbigene), CYCLIND1
(Labvision/Invitrogen), and ACTIN (Santa Cruz) were
used. In brief, C666-1 cells transfected with miRNAs or
with vector control were harvested and lysed with cold
radioimmunoprecipitation assay buffer (150 mM NaCl,
5 mM EDTA, 50 mM Tris, 1 % NP-40, 0.5 % sodium
deoxycholate, 0.1 % sodium dodecyl sulphate, and pro-
tease phosphatase inhibitor cocktail). An equal amount
of total protein from each sample was resolved on SDS-
polyacrylamide gel and transferred onto nitrocellulose
membrane (GE Healthcare UK Ltd., Little Chalfont,
UK). The membrane was blocked with 5 % non-fat milk
and was incubated with primary antibodies followed by
the corresponding secondary antibodies. Protein ex-
pression was visualized using chemiluminescence ex-
posed on X-ray films (GE Healthcare). β-actin was used
as an internal loading control in the analysis.
Fluorescence-activated cell sorting (FACS) analysis
Single-cell suspensions were rinsed twice and resuspended
in phosphate-buffered saline (PBS) (105 cells/100 μl) and
subjected to FACS analysis as previously described [7]. In
brief, for intracellular staining, cells were fixed in 70 %
ethanol and subjected to 2 % human serum blocking of
non-specific epitopes. Fluorescence-conjugated anti-CD44
(BD Biosciences, San Jose, CA, USA), anti-SOX2 and anti-
BMI1 (R&D Systems, Minneapolis, MN, USA), and anti-
OCT4 and anti-NANOG (ebiosciences, San Diego, CA,
USA) antibodies were used in this study. Respective IgG
isotypic controls were included in the experiment. At least
10,000 cells were acquired for each test sample and ana-
lyzed with a BD FACSCalibur flow cytometer (Becton
Dickinson, Franklin Lakes, NJ, USA) and Flowjo software
(Treestar/ Flowjo, LLC, Ashland, OR, USA).
Colony formation assay
Cells (1 × 103) with or without miRNA overexpression
were seeded onto 100-mm2 plates and cultured for 7–10
days. They were then washed with PBS, fixed in metha-
nol for 10 min, and stained with Giemsa stain. Experi-
ments were performed in triplicate, and colonies with at
least 50 cells (C666-1 cells of ≥ 1 mm in diameter) were
manually counted under a stereomicroscope [18] and
compared between the different groups.
In vivo tumorigenicity assay in nude mice
To evaluate the tumorigenic potential, 2x106 C666-1
cells with or without miRNA overexpression were sub-
cutaneously inoculated into the flank of female BALB/c
nude mice (nu/nu) (3 mice/group). The mice were
inspected daily for tumor formation. After 4 to 12 weeks,
the mice were killed by cervical dislocation and the tu-
mors retrieved. All experimental procedures were ap-
proved by the Animal Ethics Committee of the Chinese
University of Hong Kong.
Statistical analysis
Tests were repeated at least three times independently
for statistical calculations. Unless otherwise stated, an
unpaired t-test was used for statistical analysis of the
data. Statistical significance (P < 0.05) was determined by
PRISM5 (GraphPad Software, Inc., La Jolla, CA, USA)
and presented graphically as mean ± standard error (SE).
Results
Aberrantly downregulated expression of miR-96 and
miR-183 in NPC CSCs
The miRNA expression profiles of NPC CSCs and par-
ental C666-1 cells were determined by microarray ana-
lysis following our previous study [7]. The aberrantly
downregulated miRNAs identified in NPC CSCs are
summarized in Additional file 1: Figure S1A. Several
downregulated miRNAs including miR-200a and miR-
203 were previously reported to modulate CSC proper-
ties in NPC cells [19, 20]. Among the downregulated
miRNAs in the microarray analysis, we found that miR-
96 and miR-183 showed the highest fold changes in
NPC CSCs. Furthermore, the function of these miRNAs
in NPC has not been explored. Thus, this study focused
on elucidating the role of this cluster of miRNAs in
NPC. As shown in Fig. 1, we confirmed that only the ex-
pression of miR-96 and miR-183, but not miR-182, was
significantly downregulated in NPC CSCs when com-
pared to parental C666-1 cells. Significant downregula-
tion of miR-200a and miR-203 expression was also
detected in NPC CSCs (Additional file 1: Figure S1B).
Transient miR-96 and miR-183 expression inhibits colony
formation and anchorage-independent growth in vitro
To evaluate the function of miR-96 and miR-183 in
NPC, the effects of the ectopic expression of these miR-
NAs on cancer stem-like properties were studied in
transiently transfected C666-1 cells. Although the over-
expression of miR-96 and miR-183 showed an obviously
suppressive effect on anchorage-dependent C666-1
growth (Fig. 2a, P = 0.08), a significant inhibition in
anchorage-independent growth was observed (Fig. 2b,
P < 0.01). As shown in Fig. 2c, the inhibitory effect of
miR-96 and miR-183 overexpression on anchorage-
independent growth was negated by anti-miR-96 and
anti-miR-183 expression, respectively.
Despite the growth inhibitory effects observed above,
no aberrant expression of pluripotency-related stem cell
transcription factors OCT4, SOX2, and PcG protein
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BMI1 and cell surface marker CD44 were detected in
the NPC cells expressing miR-96 or miR-183 by flow cy-
tometry when compared with that of the negative con-
trol (Fig. 2d, all P > 0.05).
NPC cells stably expressing miR-96 and miR-183 show
reduced tumor sphere-forming capacities
To further examine the effect of overexpression of miR-
96 and miR-183 on NPC CSCs, lentiviral-based vectors
expressing miR-96 and miR-183 were used to establish
stably transfected C666-1 cells. As shown in Fig. 3a, len-
tiviral transfection of the miRNAs produced over 90 %
efficiency in C666-1 cells. The NPC cells stably express-
ing miR-96 and miR-183 were indicated by the expres-
sion of green fluorescent protein. Significantly increased
miR-96 and miR-183 expressions were detected in the
stably lentiviral-transfected C666-1 lines by qRT-PCR
when compared to that of non-transfected cells (Fig. 3a,
P < 0.05).
C666-1 cells with stable miR-183 overexpression showed
an observable decrease in the number of colonies formed
when compared to those transfected with vectors (Fig. 2b,
P = 0.18). However, no aberration was observed in colony
formation between cells stably transfected with miR-96
and those with the vector only. Interestingly, a decrease in
the number of spheres formed was observed in cells stably
expressing miR-96 or miR-183 when compared to those
with the vector (Fig. 3c). Stable overexpression of these
two miRNAs completely abolished the formation of tumor
spheres larger than 100 μm in diameter (Fig. 3c).
miR-96 and miR-183 repress stemness transcription
factors and NOTCH signals
Western blotting showed reduced expression of stem
cell transcription factors SOX2 and OCT4 in C666-1
cells stably expressing miR-96 or miR-183 (Fig. 4a). Simi-
lar BMI1 expression was noted in the stably transfected
cells and vector controls (Fig. 4a). In our previous study,
overexpression of CYCLIN D1 and activation of NOTCH
signaling were shown to play a critical role in the cell
growth and survival of NPC [21]. In the present study,
we found that the expression of NICD3 and NICD4,
two surrogate markers for activated NOTCH signaling
[22], were downregulated in the NPC cells overexpress-
ing miR-96 or miR-183 (Fig. 4a). However, no reduced
expression of CYCLIN D1 was observed in the stably
miRNA-transfected cells (Fig. 4a).
miR-183 inhibits in vivo NPC tumor formation
In Fig. 4b, the C666-1 cells stably expressing miR-183
showed a significant reduction in in vivo tumor forma-
tion when compared to those transfected with the vector
in the nude mice model (P < 0.01). However, no signifi-
cant changes were observed in the NPC cells stably ex-
pressing miR-96 (Fig. 4b).
Discussion
In our earlier study, we identified and characterized a
CSC subpopulation in EBV-positive cells [7, 8]. In the
present study, using microarray assay and qRT-PCR
analysis, we revealed that miR-96 and miR-183 are
highly repressed in NPC CSCs (Fig. 1 and Additional
file 1: Figure S1A). Although miR-96 and miR-183 have
been suggested to be oncogenic, promoting tumor cell
migration and invasion in various cancers [23–26],
studies have also shown that they play a critical role in
epithelial-mesenchymal transition, via inhibition of cell
migration and invasion, downstream of the p53-p21
pathway [27]. Inhibition of tumor cell migration and inva-
sion by these miRNAs was also reported in osteosarcoma
and pancreatic and gastric cancers [15, 16, 28, 29]. With
this study, we provide the first evidence that miR-183 ex-
erts tumor-suppressive effects on NPC by repressing CSC
properties. Overexpression of miR-183 in NPC C666-1
cells significantly inhibited cell growth and tumor forma-
tion in vivo (Figs. 2, 3 and 4). The downregulation of
stemness markers and NICDs by miR-183 also supports
its function in the inhibition of NPC CSC properties
(Fig. 4a). Recently, Tang et al. showed that miR-183 ex-
pression negatively correlates with lymph node status in
primary NPC [30]. The correlation is likely to be due to
the suppressive role of miR-183 in NPC CSCs. Emerging
Fig. 1 Down-regulation of miR-96 and miR-183 in NPC sphere-forming
cells. The expression of miR-96, miR-182, and miR-183 in sphere-forming
and parental C666-1 cells was determined by qRT-PCR. The histogram
shows the fold changes of miRNA expressions between sphere-forming
and parental C666-1 cells. Expression of miR-96 and miR-183 was
significantly decreased in sphere-forming C666-1 cells. No significant
difference in miR-182 expression was found. Student’s t-test was
used to determine statistical significance between the two groups
(n = 3, **P < 0.01, ***P < 0.001)




Fig. 2 Transient expression of miR-96 and miR-183 inhibits colony and tumor sphere formation in NPC cells. The effects of transient overexpression of
miR-96 and mi-183 on NPC cell growth were examined. a Colony formation assay of C666-1 cells with miR-96 and miR-183 overexpression. The
numbers of colonies formed by C666-1 cells transfected with miR-96 and miR-183 were obviously lower than those of the negative control
(n = 3, P = 0.08). b Tumor sphere formation in C666-1 cells expressing miR-96 and miR-183 was significantly inhibited when compared to that
of the negative control (n = 3, **P < 0.01). Representative photos of tumor spheres are shown in the right panel (magnification × 100). c No
change in tumor sphere formation in the C666-1 cells co-transfected with miR-96 or miR-183 and the corresponding anti-miR inhibitors was
observed when compared to negative controls (n = 3, all P > 0.05). Representative photos of tumor spheres are shown in the right panel
(magnification × 100). d Tumor cells expressing OCT4, NANOG, CD44, SOX2, and BMI1 were quantified by flow cytometry analysis. The histogram
shows the percentage of cells expressing these proteins in C666-1 cells transfected with miR-96 and miR-183 and that of the negative control.
No significant changes in OCT4, NANOG, CD44, SOX2, and BMI1 expression were observed in the cells transfected with miR-96 and miR-183
(n = 3, all P > 0.05). Student’s t-test was used to determine statistical significance between the two groups
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Fig. 3 Effects of stable overexpression of miR-96 and miR-183 in C666-1. a C666-1 cells stably expressing miR-96 and miR-183 were established by
lentiviral transfection. Left panel: Transfection efficiency of the transfected cells expressing green fluorescence protein (GFP) was determined under
microscopy. Representative photos show that over 90 % of the cells are visualized in green. Right panel: The expression of miR-96 or miR-186 in
the stably transfected cells was confirmed by qRT-PCR. Histograms confirmed elevated expressions of miR-96 and miR-183 in the respective cells
stably transfected with miR-96 and miR-183 (n = 3, all *P < 0.05). The effects of miR-96 and miR-183 overexpression in NPC cells were assessed by
their (b) colony-forming and (c) sphere-forming capacities. b The histogram shows the number of colonies formed in the C666-1 cells expressing
miR-96 or miR-183 compared to that of the vector control. The colony number of C666-1 cells expressing miR-183 is obviously lower than that of
the control (n = 3, P = 0.18). However, no aberration was observed in colony formation between cells stably transfected with miR-96 and those
with the vector. Representative photos of the colonies are shown in the right panel. c Both the number and size of the tumor spheres were
reduced in the C666-1 cells expressing miR-96 and miR-183. The number of tumor spheres in the C666-1 cells stably expressing miR-96 and
miR-183 and the vector control is illustrated in the histogram according to the sizes of the tumor spheres formed (<50 μm, 50–100 μm, > 100 μm)
(mean data from 6 wells of a 6-well plate per group). C666-1 cells stably expressing miR-96 and miR-183 failed to form tumor spheres of diameter larger
than 100 μm. Representative photos of the tumor spheres are shown in the right panel (magnification × 100). Lower panel: Representative
photomicrographs reveal the difference in size of the spheres between each treatment group
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evidence of the close link between stemness, drug resist-
ance and metastasis in various solid tumors [31–33] sug-
gests that targeting CSCs or their stemness properties can
complement cancer therapies. This study indicated that
according to its suppressive function in NPC CSCs, miR-
183 might be a therapeutic target for the development of
new treatment strategies.
In addition to that of miR-183, overexpression of
miR-96 transiently inhibited both anchorage-dependent
and anchorage-independent tumor cell growth (Fig. 2).
A
B
Fig. 4 Overexpression of miR-183 inhibits stemness and tumorigenic potential in C666-1 cells. a The expression of stem cell transcription factors
NICD3, NICD4, and CYCLIND D1 in the C666-1 cells stably expressing miR-96 and miR-183 was detected by Western blot. Reduced expression of
SOX2, OCT4, NICD3, and NICD4 was found in the C666-1 cells with overexpression of miR-96 or miR-183. Similar BMI and CYCLIN D1 expression
was observed in the C666-1 cells stably expressing miR-96 and miR-18 and the vector control. Beta-actin was used as the internal loading
control. The results were quantified and the histogram shows the fold changes between stable transfected cells and the vector control.
b The tumorigenic potential of the C666-1 cells stably expressing miR-96 and miR-183 was assessed by tumor growth in an in vivo nude mice
model. Significant inhibition of tumor formation was observed in the C666-1 cells stably expressing miR-183 (**P < 0.01) but not in the cells
stably expressing miR-96. Photos reveal the appearances and sizes of the tumors in each treatment group. Student’s t-test was used to determine statistical
significance between the two groups (n= 3, **P< 0.01)
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However, the growth inhibitory effect was lost in the
C666-1 cells stably expressing miR-96 (Fig. 3b). Despite
its inhibitory effect on in vitro tumor sphere formation,
the cells stably expressing miR-96 showed no significant
suppression of tumor formation in the in vivo nude
mice model (Fig. 4b). The findings indicate that miR-96
and miR-183 exert differential inhibitory effects in
C666-1 cells. It is likely that miR-96 plays a less import-
ant role in regulating CSC properties in NPC. As in our
previous study [7], the formation of tumor spheres (an-
chorage-independent growth) was used to assess CSC
properties among NPC cells. The diminished capacity
of tumor sphere formation in the NPC cells expressing
miR-96 or miR-183 suggested that these miRNAs exert
a suppressive role on the sphere-forming subpopulation
of cells (Fig. 3c). The overexpression of these miRNAs
in C666-1 cells, which resulted in the failure to form
“large” tumor spheres, may be due to the heteroge-
neous structure of the tumor spheres [34].
The diminished properties of NPC CSCs in the stable
miR-96- or miR-183-expressing NPC cells were also in-
dicated by the suppression of pluripotent stem cell tran-
scription factors SOX2 and OCT4 (Fig. 4a). Thus, prima
facie, the overexpression of miR-96 and miR-183 would
affect NPC tumorigenesis via suppression of the stem-
ness properties of NPC cells. Contrary to SOX2 and
OCT4, the expression of BMI1 was not regulated by
miR-96 or miR-183 (Fig. 4a). BMI1 is a downstream tar-
get of miR-203 [35], which was also significantly down-
regulated in NPC CSCs (Additional file 1: Figure S1B). It
is likely that the downregulation of multiple stemness-
inhibitory miRNA including miR-96, miR-183, and miR-
203 targets various pluripotent stem cell transcription
factors in NPC CSCs. The role of miR-96 and miR-183
in the regulation of NPC CSC properties was also sup-
ported by the finding of reduced NICD3 and NICD4 ex-
pression in C666-1 cells stably expressing miR-96 and
miR-183 (Fig. 4a). The NOTCH3 signaling pathway is
constitutively activated and regulated by CSC properties
in EBV-associated NPC [21]. The activated NOTCH3
signal was shown not only to confer oncogenic effects
but also cisplatin resistance in NPC cells [21]. These
findings suggest that miR-96 or miR-183 modulates NPC
CSC properties by suppressing the expression of pluri-
potent stem cell transcription factor and NOTCH signal
activity.
Conclusions
This study provides evidences supporting the stemness-
inhibitor miRNA miR-183 to be tumor suppressor in
EBV-associated NPC. Its abilities to suppress CSC prop-
erties in vitro and to effectively reduce tumor growth in
vivo shed light on its role as a potential therapeutic
target. Nevertheless, further study of the stability and
mode of delivery of miR-183 is required to develop an
efficacious miRNA-based therapeutic approach for pa-
tients with NPC.
Additional files
Additional file 1: Figure S1. (A) List of miRNAs downregulated in
C666-1 sphere-forming cells as detected by microarray analysis. (B)
Selected miRNA expressions in sphere-forming and parental C666-1
cells were detected by qRT-PCR analysis. Significant downregulation
of miR-200a, miR-96, miR-183, and miR-203 expression was found in
the nasopharyngeal carcinoma cancer stem-like cells. Student’s t-test
was used to determine statistical significance between the two
groups (n = 3, **P < 0.01, ***P < 0.001). (ODP 150 kb)
Abbreviations
CSCs, cancer stem-like cells; EBV, Epstein-Barr virus; FACS, fluorescence-
activated cell sorting; miRNA, microRNA; NPC, nasopharyngeal carcinoma;
PBS, phosphate-buffered saline; qRT-PCR, quantitative reverse transcription
and polymerase chain reaction.
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